Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VE800 and nivolumab in advanced or metastatic cancer
NCT04208958Phase 2Completed
- Sponsor
- Vedanta Biosciences
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of VE800 in melanoma, gastric cancer (GC), gastroesophageal junction adenocarcinoma, colorectal cancer (CRC), sponsored by Vedanta Biosciences. Started Jan 2020; status: completed.
02
Drugs
VE800
03
Conditions
melanomagastric cancer (GC)gastroesophageal junction adenocarcinomacolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04208958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04208958.